about
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effectsAdrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsAdrenomedullin in mammalian embryogenesis.Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell linesThe epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.Myoendocrine-like cells in invertebrates: occurrence of noncardiac striated secretory-like myocytes in the gut of the ant Formica polyctena.Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone.The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion.Adrenomedullin expression in a rat model of acute lung injury induced by hypoxia and LPS.Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement.Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.Effects of acute hypoxia and lipopolysaccharide on nitric oxide synthase-2 expression in acute lung injury.Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.Depressed adrenomedullin in the embryonic transforming growth factor-beta1 null mouse becomes elevated postnatally.Downregulation of hnRNP A2/B1 expression in tumor cells under prolonged hypoxia.Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma.Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin functionDetailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profileMesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donorsAlternative splicing of the proadrenomedullin gene results in differential expression of gene productsAndrogen-independent expression of adrenomedullin and peptidylglycine α-amidating monooxygenase in human prostatic carcinomaLight and electron microscopic study of the hindgut of the ant (Formica nigricans, hymenoptera): I. Structure of the ileumMalpighian tubules of Formica polyctena (Hymenoptera): Light and electron microscopic studyDihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agentsBiological Background of Resistance to Current Standards of Care in Multiple MyelomaPreclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
P50
Q28730433-59D368E6-C169-4AFB-BDF5-09F45F277950Q30445142-EA2E431D-48DF-4A06-B904-1E1AD5B0DA60Q34038854-D9FE0161-A5FC-4475-90D6-0797EBFBAA05Q34580825-288A83F7-3FD5-4A9D-B58A-F0BE4F4F9470Q35128148-E4DF54AC-E2FD-4900-9F80-3857F0B76D56Q37166798-1041B0CA-B334-4D87-9DB9-0FAD72805DEBQ38571231-6ED6B7FA-7007-48A8-BCD2-050F65617F92Q38751108-7BDEFB9B-1461-494A-808B-FDBCF01DE1A6Q38839531-F720CA54-00E7-42F9-9428-D382C9682BCDQ38968027-2006410A-4FE1-486D-B41F-BC9207E855AAQ39028178-8EA8CE94-C4F4-425A-AEA4-2A8A818237A3Q39399792-A6C199F0-F5D6-4719-A710-9399984B0551Q39590174-FCF744CE-0656-40BD-A41C-B5F11385D525Q40421501-8A744B55-2C89-4A03-8189-C83C54913DF7Q40484814-B9793672-E368-4804-9784-9528D6BC7B73Q40519834-E42777C7-0F96-488D-9D97-09C8E7006162Q40550067-46D8F54B-71C9-4D9E-9C2A-A30534A62E44Q40644183-8560218C-CFAE-4796-92EB-6E46BA343173Q41088379-48E2EEAE-EEC5-4A2B-9CB9-B831E034787CQ43845117-C2E89121-591F-4FE2-8587-77FDE62AF81DQ44004521-50F26FE3-DAEE-4A8A-80AD-CDBEAC53A4A5Q44541080-54EDDA72-5395-4897-B26C-D6D7B818EFEFQ47873839-14D7ABFF-3B2F-4C7A-A85E-C2C726EACE0AQ47989091-66CF683F-8985-4E4D-9AB4-372266633A01Q51693184-2F1A1D96-1BAD-4310-A3F9-AAD17D4A1152Q51703229-0B1C678B-AAC7-4A24-B331-480F4333994FQ54787043-59BDE81A-8F8E-4DC2-B050-2F54BFAB1F74Q58498450-4774B7D6-8285-477F-A7F3-E0D2928ED658Q60203403-1A0DA859-D93C-4E07-B864-BD1D07569404Q60203690-A25C60AA-0D0C-4B77-981D-0FB7E1A211B1Q61867166-5437BAB8-5B96-46CA-889F-46BEEF9C6E2FQ63966373-0AFBA0C9-7D11-42BE-9659-1FEC34B1EA61Q73224328-7A01A7A0-5D91-4C6D-9920-7AD5D923F8D1Q88980499-BDCC7EA6-D8F7-491D-A4DE-28C2C8F99EBBQ91046603-D94753D7-B2E6-408F-8C6F-277B8529B525Q91443460-3359D396-925F-4D10-816C-C239B871AA40Q92002045-48F29AE7-2235-453F-9D6F-2CCA8D6B2AB1
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mercedes Garayoa
@ast
Mercedes Garayoa
@en
Mercedes Garayoa
@es
Mercedes Garayoa
@nl
Mercedes Garayoa
@sl
type
label
Mercedes Garayoa
@ast
Mercedes Garayoa
@en
Mercedes Garayoa
@es
Mercedes Garayoa
@nl
Mercedes Garayoa
@sl
prefLabel
Mercedes Garayoa
@ast
Mercedes Garayoa
@en
Mercedes Garayoa
@es
Mercedes Garayoa
@nl
Mercedes Garayoa
@sl
P1053
O-6039-2017
P106
P31
P3829
P496
0000-0003-2194-2841